- Home
- PRFX vs VERO Comparison
PRFX vs VERO Comparison
Compare PRFX & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- VERO
- Stock Information
- Founded
- PRFX 2007
- VERO N/A
- Country
- PRFX Israel
- VERO Canada
- Employees
- PRFX N/A
- VERO N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- VERO Medical/Dental Instruments
- Sector
- PRFX Health Care
- VERO Health Care
- Exchange
- PRFX Nasdaq
- VERO Nasdaq
- Market Cap
- PRFX 3.0M
- VERO 2.4M
- IPO Year
- PRFX 2020
- VERO N/A
- Fundamental
- Price
- PRFX $3.16
- VERO $0.31
- Analyst Decision
- PRFX Hold
- VERO
- Analyst Count
- PRFX 1
- VERO 0
- Target Price
- PRFX N/A
- VERO N/A
- AVG Volume (30 Days)
- PRFX 3.2M
- VERO 128.1K
- Earning Date
- PRFX 01-01-0001
- VERO 03-31-2025
- Dividend Yield
- PRFX N/A
- VERO N/A
- EPS Growth
- PRFX N/A
- VERO N/A
- EPS
- PRFX N/A
- VERO N/A
- Revenue
- PRFX N/A
- VERO $67,200,000.00
- Revenue This Year
- PRFX N/A
- VERO N/A
- Revenue Next Year
- PRFX N/A
- VERO $4.95
- P/E Ratio
- PRFX N/A
- VERO N/A
- Revenue Growth
- PRFX N/A
- VERO N/A
- 52 Week Low
- PRFX $0.43
- VERO $0.28
- 52 Week High
- PRFX $16.63
- VERO $1.59
- Technical
- Relative Strength Index (RSI)
- PRFX 49.34
- VERO 38.70
- Support Level
- PRFX $3.22
- VERO $0.30
- Resistance Level
- PRFX $5.47
- VERO $0.32
- Average True Range (ATR)
- PRFX 0.34
- VERO 0.02
- MACD
- PRFX 0.04
- VERO -0.00
- Stochastic Oscillator
- PRFX 15.97
- VERO 12.62
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.